EScitalopram PIndolol ONset of Action

• Status: Terminated
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Markus KOSEL
• Collaborators: H. Lundbeck A/S; University Hospital, Basel, Switzerland; University Hospital, Geneva; University of Lausanne Hospitals
• Treatments: Citalopram; Dexetimide; Pindolol

Criteria

Inclusion Criteria:

• patients aged between 18 and 65 years old

• patients suffering from major depression according to DSM-IV with a MADRS score of at least 25 and not treated by an antidepressant at the time of inclusion with the exception of non-responders to antidepressant for a period of at least 6 weeks or not tolerating an ongoing antidepressant necessitating a change of the antidepressant(excluding fluoxetine and irreversible MAOI)

• informed consent

Exclusion criteria:

• any other Axis I disorder excluding anxiety disorder not dominating the clinical picture, nicotine abuse

• non-responders to escitalopram in the past

• already taking pindolol

• pregnancy and breast feeding

• contraindication to one of the two treatments (medical conditions, drug treatments)

• significant somatic comorbidity interfering with the study procedures

• high risk of suicidality

• women of childbearing age not having a safe means of contraception